As the first cohort of patients are dosed in the Phase II trial, multiple new trial sites are added for the glioblastoma ...

SELLAS has announced positive data from preclinical studies identifying the ASXL1 mutation as a predictor of response to ...

Anocca has submitted its first clinical trial application (CTA) for conducting the Phase I/II VIDAR-1 trial to the EMA.

Aulos Bioscience has announced the first patients have been dosed as part of a trial investigating avelumab, marketed as ...